Research news A University of Texas at El Paso study has found that people with type 2 diabetes or obesity who used glucagon-like peptide-1 receptor agonists had lower odds of alcohol, opioid, nicotine and cocaine use disorders, although researchers said clinical trials were needed before the drugs could be considered for addiction treatment A study led by researchers at The University of Texas at El Paso, USA, has found that the use of diabetes and weight loss medicines such as Ozempic was associated with a lower risk of alcohol, opioid, nicotine and cocaine use disorders
Kennedy has also criticized GLP-1 weight-loss medications, including Ozempic, Wegovy, Mounjaro, and Zepbound
Things are going great with this
The science behind the results Retatrutide is not just another weight loss shot
In metabolic cages, Gipr AP-KO mice showed reduced intake of HFD (Fig